Related Experiment Video
Updated: Jan 12, 2026

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride CCl4 Exposure Through an Orogastric Tube
Published on: April 28, 2020
From Therapy to Toxicity: A Rare Case of Acute Piperacillin/Tazobactam-Associated Drug-Induced Liver Injury
Priya Kumari Maheshwari1,2, Alexis Maddox3, Jun Yoo2
1Department of Internal Medicine, University of Central Florida, Pensacola, USA.
Abstract:
Drug-induced liver injury (DILI) is a diagnosis of exclusion, but one that requires high clinical suspicion because prompt withdrawal of the offending agent is imperative to improve prognosis. Piperacillin/tazobactam (TZP) is a rare cause of clinically apparent liver injury. This case is an example of DILI caused by TZP that was identified when a hospitalized patient's liver enzymes greatly increased, and hepatic steatosis was subsequently seen on a computed tomography scan. The Roussel Uclaf Causality Assessment Method (RUCAM) score is a tool used to indicate the likelihood of DILI. In this case, the RUCAM score was 7, indicating that the causality assessment of the TZP as the cause of liver injury was probable. This case underscores the importance of maintaining a high index of suspicion for DILI, particularly in patients receiving extended courses of antibiotics, and highlights the need for routine liver function monitoring during therapy with agents known to carry hepatotoxic potential.
Insights
Drug-induced liver injury (DILI) from piperacillin/tazobactam (TZP) is rare but serious. Promptly identifying and stopping the antibiotic is crucial for patient recovery and prognosis.
Area of Science:
- Hepatology
- Pharmacology
- Internal Medicine
Background:
- Drug-induced liver injury (DILI) necessitates high clinical suspicion for prompt intervention.
- Piperacillin/tazobactam (TZP) is an uncommon but significant cause of DILI.
- Early recognition and cessation of the causative agent are vital for improving patient outcomes.
Related Concept Videos
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Prevention of Further Absorption of Poison
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

